Navigation Links
Biohaven Files Registration Statement for Proposed Public Offering of its Common Shares
Date:4/8/2017

TORONTO, April 7, 2017 /PRNewswire/- Portage Biotech Inc. ("Portage") (OTC: PTGEF, Canadian Securities Exchange: PBT.U) announced today that Biohaven Pharmaceutical Holding Company Ltd. ("Biohaven"), in which Portage holds an equity interest of approximately 28.3%, issued a press release today announcing that it filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (the "SEC") relating to a proposed offering of its common shares.

A copy of the preliminary prospectus, when available, may be obtained by mail from the offices of Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, New York 10014; or from Piper Jaffray & Co., Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, or by telephone at (800) 747-3924, or by email at prospectus@pjc.com; or from Barclays Capital Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, telephone: (888) 603-5847, e-mail: Barclaysprospectus@broadridge.com.

A registration statement relating to these securities has been filed with the SEC but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective.  This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. 

About Biohaven

Biohaven is a clinical-stage biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurological diseases, including rare disorders. Biohaven has licensed intellectual property from companies and institutions including Bristol-Myers Squibb Company, AstraZeneca AB, Yale University, Catalent, ALS Biopharma LLC and Massachusetts General Hospital.  Biohaven is a company organized under the laws of the British Virgin Islands and its United States operations are based in New Haven, Connecticut.

About Portage

Portage is engaged in the discovery and development of pharmaceutical and biotech products through clinical "proof of concept" with a focus on areas of unmet clinical need. Following proof of concept, Portage will seek to sell or license these products to large pharmaceutical or biotechnology companies for further development and commercialization. Portage has an interest in novel targeted therapies, stem cell therapies, and new indications for older marketed products that have been found to have novel patentable characteristics that bring new value to patients.

Forward-Looking Statements

This news release includes forward-looking statements within the meaning of the U.S. federal and Canadian securities laws.  Any such statements reflect Portage's current views and assumptions about future events and financial performance.  Portage cannot assure that future events or performance will occur. Important risks and factors that could cause actual results or events to differ materially from those indicated in our forward-looking statements.

Portage assumes no obligation and expressly disclaims any duty to update the information in this News Release.


'/>"/>
SOURCE Portage Biotech Inc.
Copyright©2017 PR Newswire.
All rights reserved


Related biology technology :

1. Portages Biohaven enters into exclusive formulation agreement and global license with Catalent for lead product
2. Portages Biohaven Announces Agreement with inVentiv Health
3. Portages Biohaven to begin Phase 1 study in 3Q2015 and readying for Phase 3 study start by 1Q2016
4. Portages Biohaven Announces IND Filing for BHV-0223 for Phase 1 Clinical Testing
5. Portages Biohaven Acquires Intellectual Property for Portfolio of Prodrugs from ALS Biopharma, LLC
6. Portages Biohavens lead drug candidate clears FDA Investigational New Drug Application (IND) review and clinical studies to begin
7. Portages Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223
8. Biohaven and Fox Chase Chemical Diversity Center Announce Strategic Alliance in Early Stage Drug Discovery Research
9. Portages Biohaven Completes Multiple Dose Phase of Pharmacokinetic Trial with BHV-0223
10. Portages Biohaven announces Phase 1 pharmacokinetic study meets study objectives and supports advancing BHV-0223 and also appoints a CEO
11. Biohaven Announces Phase 1 Pharmacokinetic Study Meets Study Objectives and Supports Advancing BHV-0223
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2019)... ... 22, 2019 , ... Artemis (formerly Agrilyst), the leading enterprise Cultivation ... round co-led by Astanor Ventures and Talis Capital with participation ... iSelect Fund . The company has raised $11.75m to date and will use the ...
(Date:5/15/2019)... Pa. (PRWEB) , ... May 15, 2019 , ... Milton ... Year in recognition for his work within the biomedical industry, where he is changing ... improved medical devices. , “William Harding epitomizes the vision of our founders – ...
(Date:5/14/2019)... ... May 13, 2019 , ... Leak Detection Associates (LDA), ... Pharmaceutical, Biotechnology, Medical Device and Food Packaging Industries’ is excited to announce the ... improve LDA’s ability to communicate directly with the marketplace; serving as a destination ...
(Date:5/8/2019)... , ... May 07, 2019 , ... Standing at 16.2 hands, Atlas is on the ... in a drill team and barrel racing, among other activities. When loping around a ... He went from being a busy horse to only being able to walk. Fortunately ...
Breaking Biology Technology:
(Date:6/18/2019)... , ... June 18, 2019 , ... ... learning cloud solutions, today introduced Data Science Workstations-as-a-Service as part of its dedicated, ... from BOXX Technologies, Cirrascale Data Science Workstations feature NVIDIA® Quadro RTX™ GPUs for ...
(Date:6/16/2019)... , ... June 14, 2019 , ... ... Oracle Cloud customer, will deliver a joint presentation with Versiti’s CIO at the ... 16-19 at the Rosen Shingle Creek Resort. , Versiti Vice President and Chief ...
(Date:6/13/2019)... ... ... KICVentures announced today its plans to host an event at Becker’s 17th ... Chicago on Thursday, June 13th at 6:30 pm. The event will take place at ... Ticino Hospitality room in space #74T. , The event will feature three brief talks ...
Breaking Biology News(10 mins):